36 results about "Antigen Processing Cell" patented technology

An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dendritic cells infected with the virus are useful immunotherapeutic methods of treating disease.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+and CD4+T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognized by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.

There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises a portion of the region 40-60 of myelin oligodendrocyte glycoprotein (MOG). In particular there is provided an apitope which is selected from the following myelin oligodendrocyte glycoprotein peptides: MOG 41-55, 43-57, 44-58 and 45-59. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and / or prevent a disease using such a peptide.

The present invention provides a tandem expression of common antigenic epitopes of feline calicivirus GI and GII strain groups and the establishment of an indirect ELISA method. Using a prokaryotic expression vector, multiple B cell antigens of feline calicivirus VP1 protein were expressed in tandem. The expressed recombinant protein was purified and used as a coating antigen for the detection of feline calicivirus antibodies. A parallel comparison with the method of encapsulating whole virus showed that the value of detecting negative and positive sera was highly consistent. The antigen processing of the invention is convenient, the test time is shortened, and the operation steps are simpler. The invention establishes an indirect ELISA method for detecting the antibody level of feline calicivirus in cat serum, has the characteristics of good repeatability and high specificity, and can be used for feline calicivirus serological investigation. Therefore, the feline calicivirus indirect ELISA detection kit based on the tandem expression of the VP1 protein B cell antigen provided by the present invention is very suitable for the detection of large clinical samples, and is suitable for large-scale promotion.

The present invention provides methods for antigen and / or bioactive molecule delivery to antigen presenting cells utilizing ASC specks as vehicles; 1) the ASC speck composition is made of ASC protein(s) and the antigen and / or bioactive molecule(s) purified from cells as a compact micro-spherical structure; 2) purified micro-spherical ASC speck delivery vehicles are stable at 37° C. for more than 30 days; and 3) antigen and / or bioactive molecules carried by ASC specks can be efficiently phagocytosed by antigen presenting cells and their degradation in the lysosome allows antigen processing and presentation.

The present invention provides peptides partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides peptides comprising the sequence DNIMVTFRNQASRPY or PRCLTRYYSSFVNME with modifications at the N- and C-termini. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and / or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.